Dinutuximab binds GD2 on tumor cells and recruits Fcγ receptor–bearing effector cells (including CD64+ cells) to mediate ADCC/ADCP and activates complement (CDC) to kill GD2+ targets; CD64-expressing cells act as effectors, not targets.